Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 2/3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 19Neutropenia 13Hodgkin Disease 5Lymphoma 4Lymphoma, Large B-Cell, Diffuse 3Chemotherapy-induced Neutropenia 3Triple Negative Breast Neoplasms 2Febrile Neutropenia 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Recurrent Uterine Corpus Carcinoma 1Rectal Neoplasms 1Neurofibrosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1Fever 1Endometrial Adenocarcinoma 1

Interventions

pegfilgrastim 3NPI 2358 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Docetaxel 2balugrastim 1Drug Therapy 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Chemotherapy-induced Neutropenia × pegfilgrastim × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡